Olesoxime
Small moleculeexperimental
Clinical trial activity
16 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started May 1, 2007 (NCT00496457)
Timeline
Indications
Studied for
- Amyotrophic Lateral Sclerosis · Phase 2/Phase 3
- Colorectal Neoplasms · Phase 1/Phase 2
- Diabetic Neuropathies · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Healthy Volunteers · Phase 1
- Multiple Sclerosis, Relapsing-Remitting · Phase 1
- Muscular Atrophy, Spinal · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 2
- Shock · Phase 2/Phase 3
- Spinal Diseases · Phase 2
- Spinal Muscular Atrophies of Childhood · Phase 2
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=NO)CC[C@]4(C)[C@H]3CC[C@]12C- Mol. weight
- 399.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545254 ↗
Also known as
- cholest-4-en-3-one, oxime
- olesoxime
- olesoxime
- olesoxime
- olesoxime
- tro19622
- tro19622
- tro19622
- tro19622
- tro-19622
- tro-19622
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04068610 | Phase 1/Phase 2 (Phase 2) | Aug 29, 2019 | MedImmune |
| NCT03743753 | N/A | May 1, 2019 | McMaster University |
| NCT03812341 | N/A | Aug 10, 2018 | University of California, Irvine |
| NCT03608514 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2018 | National Hepatology & Tropical Medicine Research Institute |
| NCT03725566 | N/A | May 22, 2018 | Capital Medical University |
| NCT03260686 | N/A | Nov 28, 2016 | University of Leeds |
| NCT02886130 | N/A | Aug 29, 2016 | University of Montreal |
| NCT02628743 | Phase 2 | Jan 20, 2016 | Roche |
| NCT02835976 | Phase 1 | Jul 1, 2014 | Roche, Trophos |
| NCT01808885 | Phase 1 | Apr 1, 2013 | Aix-University of Marseille, Roche, SGS Life Sciences, STRAGEN, University of Reims, University of Rennes |
| NCT01302600 | Phase 2 | Nov 1, 2010 | Bambino Gesù Hospital and Research Institute, Roche |
| NCT01285583 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2010 | Roche, University of Paris |
| NCT00868166 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2009 | European Commission, Trophos, University of Paris |
| NCT00876538 | Phase 2 | Mar 1, 2009 | Roche |
| NCT00666016 | Phase 2 | Apr 1, 2008 | Roche, University of Paris |
| NCT00496457 | Phase 2 | May 1, 2007 | Ergomed, Roche, Trophos |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 8 | 8 | 3 | 2007 |
| Trophos | For profit | 3 | 1 | 3 | 2007 |
| University of Paris | Academic/Hospital | 3 | 0 | 2 | 2008 |
| Aix-University of Marseille | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Bambino Gesù Hospital and Research Institute | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Ergomed | For profit | 1 | 0 | 1 | 2007 |
| European Commission | Government | 1 | 0 | 1 | 2009 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| MedImmune | For profit | 1 | 1 | 1 | 2019 |
| National Hepatology & Tropical Medicine Research Institute | Government | 1 | 1 | 1 | 2018 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2013 |
| STRAGEN | For profit | 1 | 0 | 1 | 2013 |
| University of California, Irvine | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Leeds | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Montreal | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Reims | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Rennes | Academic/Hospital | 1 | 0 | 1 | 2013 |
18 organizations
Page 1 / 1